Oncolytics Biotech® Inc. Announces 2011 Year End Results

CALGARY, March 15, 2012 /PRNewswire/ – Oncolytics Biotech Inc. (TSX:ONC,
NASDAQ:ONCY) (“Oncolytics” or the “Company”) today announced its
financial results and operational highlights for the year ended
December 31, 2011.

“In the last year we made substantial progress as we announced positive
clinical trial results and started clinical trials in additional cancer
indications while maintaining the strength of our balance sheet,” said
Dr. Brad Thompson, President and CEO of Oncolytics. “Our primary focus
in the near term remains completing enrollment in the first stage of
our Phase III study in head and neck cancers with the support of an
increasing number of enrolling centres in Europe and North America.”

Selected Highlights

Since January 1, 2011, the Company has made a number of significant

Clinical Trial Results

  • Presented interim data from a Phase II clinical trial using intravenous
    administration of REOLYSIN® in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer (REO 017) indicating that
    the clinical study had successfully reached its primary endpoint, and
    that the drug combination was active. Eight patients of 13 evaluable
    patients in the study had stable disease (SD) for 12 weeks or longer,
    for a clinical benefit rate (complete response (CR) + partial response
    (PR) + SD) of 62%. An additional patient had an unconfirmed PR of less
    than six weeks. Seventeen evaluable patients with pancreatic cancer
    were expected to be treated in the first stage and if three or more
    patients received clinical benefit, the study would then proceed to the
    next stage. This endpoint was met after six evaluable patients were

  • Presented positive results from a Phase II clinical trial (REO 015)
    using intravenous administration of REOLYSIN in combination with
    paclitaxel and carboplatin in patients with advanced head and neck
    cancers at the AACR-NCI-EORTC International Conference on Molecular
    Targets and Cancer Therapeutics. Of the 13 patients evaluable for
    response, four had PRs, for an objective response rate of 31%. Six
    patients had SD or better for 12 weeks or longer for a disease control
    rate (SD or better) of 46%. Two of the four patients with PRs and both
    patients with SD had received prior treatment with taxanes;

  • The presentation of interim preliminary results from a Phase II clinical
    trial using intravenous administration of REOLYSIN in combination with
    paclitaxel and carboplatin in patients with non-small cell lung cancer
    (NSCLC) with Kras or EGFR-activated tumours at the International Association for the
    Study of Lung Cancer World Conference on Lung Cancer. As of the
    presentation date, response evaluation in 21 patients showed six PR
    (28.6%), 13 SD (61.9%) and two progressive disease (PD) (9.5%),
    translating into a clinical benefit rate (complete response (CR) + PR +
    SD) of 90.5% and a response rate (CR + PR) of 28.6%;

  • Interim data from a U.K. translational clinical trial (REO 013)
    investigating intravenous administration of REOLYSIN in patients with
    metastatic colorectal cancer prior to surgical resection of liver
    metastases. On initial histological analysis of the 10 treated
    patients, there was evidence of selective delivery of virus to tumour
    versus normal liver and viral replication in the majority (seven) of

Ongoing Clinical Program

  • Entry into an agreement whereby the NCIC Clinical Trials Group (CTG) at
    Queen’s University in Kingston, Ontario, will sponsor and conduct a
    randomized Phase II study of REOLYSIN in patients with recurrent or
    metastatic castration resistant prostate cancer enrolling up to 80

  • Agreement with the Cancer Therapy Evaluation Program, Division of Cancer
    Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is
    part of the National Institutes of Health, to sponsor a Phase I study
    of REOLYSIN alone in patients with relapsed multiple myeloma;

  • The opening of enrollment in a U.S. Phase 1 study of REOLYSIN in
    combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil
    (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant
    Kras mutant colorectal cancer (REO 022);

  • Start of enrollment in a 2-Arm randomized Phase II study of carboplatin,
    paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the
    first line treatment of patients with recurrent or metastatic
    pancreatic cancer sponsored by the NCI;

  • Completion of enrollment in a U.S. Phase II clinical trial using
    intravenous administration of REOLYSIN in combination with paclitaxel
    and carboplatin in patients with advanced head and neck cancers (REO


  • SAFC®, a Division of Sigma-Aldrich Corporation, commenced validation
    activities designed to demonstrate the manufacturing process for the
    commercial production of REOLYSIN is robust and reproducible;

  • A commercial supply agreement with SAFC for the commercial manufacture
    of REOLYSIN. Under the terms of the agreement, SAFC will perform
    process validation of the product, will continue to supply clinical
    requirements and will supply commercial material upon approval of the

Preclinical Program

  • The posting of a study in the online version of Molecular Therapy, a
    publication of The American Society of Gene and Cell Therapy,
    investigating the timing of chemotherapy delivery that optimizes the
    efficacy of systemic REOLYSIN. The paper, authored by Kottke et al.,
    was entitled “Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for
    Successful Systemic Oncolytic Virotherapy.”
    It describes when best to administer taxanes with reovirus to optimize
    viral delivery to the tumor mass. The researchers demonstrated that
    this drug combination yielded superior results to either treatment
    alone. They were able to reproducibly cure nearly half of the treated
    animals by employing this optimized schedule of paclitaxel/REOLYSIN;


  • Closed bought deal financing, that had been increased to $18.5 million
    from $15 million, for gross proceeds of $21.3 million following the
    full exercise of the over-allotment option by the syndicate of
  • Pursuant to the acceleration of the expiry date of those warrants issued
    on November 23, 2009, the Company received proceeds of approximately
    US$6.8 million resulting from the exercise of 1,943,000 warrants;
  • The exercise of 1,322,750 warrants, issued in connection with the
    financing that closed on November 8, 2010, providing the Company with
    proceeds of approximately $8.2 million;


  • The appointment of Gerard Kennealey, MD as Senior Vice President of
    Clinical Development and Chief Medical Officer (CMO). Dr. Kennealey
    most recently held the position of Vice President of Scientific Affairs
    at Cephalon Inc.; and
  • The appointment of George M. Gill, MD as Senior Vice President of
    Regulatory Affairs and Chief Safety Officer. Dr. Gill has been an
    officer of Oncolytics since 2002.

    December 31,     December 31,     January 1,
    2011     2010     2010
    $     $     $
Current assets                
Cash and cash equivalents   32,918,751     39,296,682     32,448,939
Short-term investments   1,936,787     3,609,246     1,679,937
Accounts receivable   55,392     284,988     64,787
Prepaid expenses   721,576     278,934     507,408
Total current assets   35,632,506     43,469,850     34,701,071
Non-current assets                
Property and equipment   392,111     226,911     208,320
Long term investment           684,000
Total non-current assets   392,111     226,911     892,320
Asset held for sale       735,681    
Total assets   36,024,617     44,432,442     35,593,391
Liabilities And Shareholders’ Equity                
Current Liabilities                
Accounts payable and accrued liabilities   6,504,238     2,500,682     4,226,933
Warrant liability       5,536,800     1,023,051
Total current liabilities   6,504,238     8,037,482     5,249,984
Shareholders’ equity                
Share capital                
  Authorized: unlimited   
December 31, 2011 – 71,251,335  
December 31, 2010 –  67,958,302  
January 1, 2010 – 61,549,969
  177,282,566     155,439,610     131,908,274
Warrants   2,653,627     4,108,652     2,437,460
Contributed surplus   21,142,519     19,399,489     13,734,743
Accumulated other comprehensive loss   (117,501)     (156,660)    
Accumulated deficit   (171,440,832)     (142,396,131)     (117,737,070)
Total shareholders’ equity   29,520,379     36,394,960     30,343,407
Total liabilities and equity   36,024,617     44,432,442     35,593,391

      2011       2010
For the years ending December 31,      $        $
Research and development     23,386,685       13,882,565
Operating     5,334,582       6,003,870
Loss before the following     (28,721,267)       (19,886,435)
Write down of asset available for sale     (735,681)      
Change in fair value of warrant liability     36,000       (4,841,949)
Interest     416,247       76,934
Loss before income taxes     (29,004,701)       (24,651,450)
Income tax expense     (40,000)       (7,611)
Net loss     (29,044,701)       (24,659,061)
Other comprehensive gain (loss) – translation adjustment     39,159       (156,660)
Net comprehensive loss     (29,005,542)       (24,815,721)
Basic and diluted loss per common share     (0.41)       (0.39)
Weighted average number of shares (basic and diluted)     70,911,526       62,475,403

    Share Capital   Warrants   Contributed
    $   $   $   $   $   $
As at January 1, 2010   131,908,274   2,437,460   13,734,743     (117,737,070)   30,343,407
Net loss and comprehensive loss         (156,660)   (24,659,061)   (24,815,721)
Issue of common shares, public offering   22,639,719   4,120,201         26,759,920
Exercise of warrants   787,508   (11,009)         776,499
Exercise of stock options   104,109     (24,295)       79,814
Expired warrants     (2,438,000)   2,438,000      
Share based compensation       3,251,041       3,251,041
As at December 31, 2010   155,439,610   4,108,652   19,399,489   (156,660)   (142,396,131)   36,394,960
Net loss and comprehensive income         39,159   (29,044,701)   (29,005,542)
Exercise of warrants   21,487,080   (1,455,025)         20,032,055
Exercise of stock options   355,876     (62,473)       293,403
Share based compensation       1,805,503       1,805,503
As at December 31, 2011   177,282,566   2,653,627   21,142,519   (117,501)   (171,440,832)   29,520,379



For the years ending December 31,     $        $ 
Operating Activities              
Net loss for the year     (29,044,701)       (24,659,061)
  Amortization – property and equipment     92,590       63,156
  Share based compensation     1,805,503       3,251,041
  Change in fair value of warrant liability     (36,000)       4,841,949
  Write down of asset available for sale     735,681      
  Unrealized foreign exchange loss     115,234       343,821
Net change in non-cash working capital     3,790,510       (1,717,978)
Cash used in operating activities     (22,541,183)       (17,877,072)
Investing Activities              
Acquisition of property and equipment     (257,790)       (81,846)
Acquisition of investment           (51,681)
Redemption (purchase) of short-term investments     1,672,459       (1,929,309)
Cash provided by (used in) investing activities     1,414,669       (2,062,836)
Financing Activities              
Proceeds from exercise of stock options and warrants     14,824,658       528,211
Proceeds from public offering           26,759,921
Cash provided by financing activities     14,824,658       27,288,132
Increase (decrease) in cash     (6,301,856)       7,348,224
Cash and cash equivalents, beginning of year     39,296,682       32,448,939
Impact of foreign exchange on cash and cash equivalents     (76,075)       (500,481)
Cash and cash equivalents, end of year     32,918,751       39,296,682

To view the Company’s Fiscal 2011 Consolidated Financial Statements,
related Notes to Consolid
ated Financial Statements, and Management’s Discussion and Analysis,
please see the Company’s quarterly filings which will be available on
www.sedar.com and on www.oncolyticsbiotech.com

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of human trials
including a Phase 3 trial in head and neck cancers using REOLYSIN, its
proprietary formulation of the human reovirus. For further information
about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended.  Forward-looking statements, including the Company’s belief as
to the potential of REOLYSIN as a cancer therapeutic; the Company’s
expectations as to the success of its research and development programs
in 2012 and beyond, the Company’s planned operations, the value of the
additional patents and intellectual property; the Company’s
expectations related to the applications of the patented technology;
the Company’s expectations as to adequacy of its existing capital
resources; the design, timing, success of planned clinical trial
programs; and other statements related to anticipated developments in
the Company’s business and technologies involve known and unknown risks
and uncertainties, which could cause the Company’s actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
efficacy of REOLYSIN as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company’s ability to
successfully commercialize REOLYSIN, uncertainties related to the
research and development of pharmaceuticals, uncertainties related to
the regulatory process and general changes to the economic
environment.  Investors should consult the Company’s quarterly and
annual filings with the Canadian and U.S. securities commissions for
additional information on risks and uncertainties relating to the
forward-looking statements.  Investors are cautioned against placing
undue reliance on forward-looking statements.  The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.



SOURCE Oncolytics Biotech Inc.